SNN - Smith & Nephew SNATS - Stock & Dividends

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US83175M2052

Knee Implants, Hip Implants, Surgical Instruments, Wound Care Products, Orthopedic Devices

Smith & Nephew plc is a leading medical technology company that designs, manufactures, and markets a wide range of innovative medical devices and services globally. The company operates through three main segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

In the Orthopaedics segment, Smith & Nephew offers a comprehensive portfolio of products for joint reconstruction, including knee and hip implants for replacement and revision procedures, as well as trauma and extremities products for fracture stabilization and deformity correction. These products are designed to improve patient outcomes and quality of life.

The Sports Medicine & ENT segment focuses on sports medicine joint repair products, which include instruments, technologies, and implants for minimally invasive surgery. These products are used to treat soft tissue injuries and degenerative conditions affecting the shoulder, knee, hip, and small joints. Additionally, the company offers arthroscopic enabling technologies, such as fluid management equipment, high-definition cameras, and hand instruments, to assist with visualization and tissue resection during surgical procedures.

In the Advanced Wound Management segment, Smith & Nephew provides a range of products for the treatment and prevention of acute and chronic wounds, including leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds. The company's advanced wound care products include bioactives, such as biologics and other bioactive technologies, for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes. Furthermore, the company offers advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems.

Smith & Nephew plc serves healthcare providers globally, providing innovative solutions to improve patient care and outcomes. With a rich history dating back to 1856, the company is headquartered in Watford, the United Kingdom, and is committed to delivering high-quality products and services that make a meaningful difference in people's lives.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for SNN - Smith & Nephew SNATS  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for SNN - Smith & Nephew SNATS  - Stock & Dividends

SNN Stock Overview

Market Cap in USD 10,824m
Sector Healthcare
Industry Medical Devices
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 1999-11-16

SNN Stock Ratings

Growth 5y -35.1
Fundamental 55.3
Dividend 35.18
Rel. Performance vs Sector -0.09
Analysts 4.25/5
Fair Price Momentum 27.11 USD
Fair Price DCF 13.12 USD

SNN Dividends

Dividend Yield 12m 2.64%
Yield on Cost 5y 1.92%
Dividends CAGR 5y 0.60%
Payout Consistency 95.6%

SNN Growth Ratios

Growth 12m -5.51%
Growth Correlation 12m -8%
Growth Correlation 3m 48%
CAGR 5y -6.12%
CAGR/Mean DD 5y -0.21
Sharpe Ratio 12m -0.48
Alpha vs SP500 12m -33.81
Beta vs SP500 5y weekly 1.09
ValueRay RSI 98.84
Volatility GJR Garch 1y 22.04%
Price / SMA 50 11.07%
Price / SMA 200 11.77%
Current Volume 1155.5k
Average Volume 20d 925.4k

External Links for SNN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of SNN stocks?
As of July 13, 2024, the stock is trading at USD 28.40 with a total of 1,155,540 shares traded.
Over the past week, the price has changed by +5.93%, over one month by +9.65%, over three months by +19.48% and over the past year by -5.02%.
What are the forecast for SNN stock price target?
According to ValueRays Forecast Model, SNN Smith & Nephew SNATS will be worth about 29.9 in July 2025. The stock is currently trading at 28.40. This means that the stock has a potential upside of +5.42%.
Issuer Forecast Upside
Wallstreet Target Price 30.5 7.29
Analysts Target Price 31.3 10.3
ValueRay Target Price 29.9 5.42